Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Syndax Pharmaceuticals Inc shares valued at $2,582,021 were sold by Metzger Michael A on Sep 08 ’25. At $16.41 per share, Metzger Michael A sold 157,307 shares. The insider’s holdings dropped to 298,661 shares worth approximately $6.13 million following the completion of this transaction.
Also, MICHAEL METZGER purchased 157,307 shares, netting a total of over 2,680,511 in proceeds.
Before that, Podlesak Dennis had sold 19,200 shares from its account. In a trade valued at $304,170, the Director traded Syndax Pharmaceuticals Inc shares for $15.84 each. Upon closing the transaction, the insider’s holdings decreased to 19,200 shares, worth approximately $3.93 million.
Earlier on August 05, 2025, BTIG Research resumed its rating. Their recommendation was “a Buy” for SNDX stock.
Analyzing SNDX Stock Performance
On last trading session, Syndax Pharmaceuticals Inc [NASDAQ: SNDX] rose 1.43% to $20.52. The stock’s lowest price that day was $20.065, but it reached a high of $20.63 in the same session. During the last five days, there has been a surge of approximately 0.24%. Over the course of the year, Syndax Pharmaceuticals Inc shares have jumped approximately 56.88%.
Is Syndax Pharmaceuticals Inc subject to short interest?
Stocks of Syndax Pharmaceuticals Inc saw a sharp steep in short interest on 2025-12-31 dropping by -2.65 million shares to 22.57 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 25.22 million shares. A decline of -11.75% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 14.53 of the overall float, the days-to-cover ratio (short ratio) decline to 14.53.
Which companies own the most shares of Syndax Pharmaceuticals Inc (SNDX)?
In terms of Syndax Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 38 in the next 12 months, up nearly 87.84% from the previous closing price of $20.23. Analysts anticipate Syndax Pharmaceuticals Inc stock to reach 44 by 2026, with the lowest price target being 35. In spite of this, 4 analysts ranked Syndax Pharmaceuticals Inc stock as Buy at the end of 2026. On July 10, 2025, Goldman assigned a price target of “a Buy” to the stock and initiated coverage with a $18.
